scholarly journals Chitosan oligosaccharide (GO2KA1) improves postprandial glycemic response in subjects with impaired glucose tolerance and impaired fasting glucose and in healthy subjects: a crossover, randomized controlled trial

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Sarang Jeong ◽  
Jung Min Cho ◽  
Young-In Kwon ◽  
Seong-Chul Kim ◽  
Dong Yeob Shin ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Healthy Subjects ◽  
Fasting Glucose ◽  
Test Group ◽  
Postprandial Blood Glucose ◽  
Chitosan Oligosaccharide ◽  
Glucose Levels ◽  
Blood Glucose Levels

Abstract Background The antidiabetic and hypoglycemic effects of chitosan have been reported in previous studies. We have previously shown that chitosan oligosaccharide reduces postprandial blood glucose levels in vivo. We conducted a short-term crossover study to support the results of the previous study. Methods The study was a randomized, double-blind, controlled crossover trial completed at one clinical research site. Subjects with impaired glucose tolerance and impaired fasting glucose and healthy subjects were randomly assigned to consume one of two different experimental test capsules that differed in only the sample source (GO2KA1 vs placebo), and all subjects were instructed to consume the 75 g sucrose within 15 min. After a 7-day interval, the subjects consumed the other capsules that were not consumed on the first day. We assessed blood glucose levels using a 2-h oral sucrose tolerance test. The study was registered at clinicaltrials.gov (NCT03650023). Results The test group showed significantly lower blood glucose levels at 60 min (p = 0.010) and postprandial blood glucose areas under the curve (p = 0.012). The change in blood glucose levels at 60 min was significantly lower in the test group than in the placebo group (p = 0.017). Conclusions Based on the results of this study, the consumption of chitosan oligosaccharide (GO2KA1) supplements with a meal can effectively reduce postprandial blood glucose levels, which is relevant to the prevention of diabetes.

scholarly journals Screening of newly-diagnosed adults with Tuberculosis for Diabetes mellitus and Impaired Glucose Tolerance in a Local Government Area in Ogun State, Nigeria

2019 ◽  
pp. 146-155
Author(s):  
AA Salako ◽  
OA Adenowo ◽  
OE Amoran ◽  
O Odusan ◽  
GJ Mautin ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Treatment Outcomes ◽  
Fasting Blood Glucose ◽  
Newly Diagnosed ◽  
Glucose Levels ◽  
Ogun State ◽  
Blood Glucose Levels

Background: Emerging patterns in epidemiological transitions have led to increased risk for Non-Communicable Diseases and infectious conditions globally. Diabetes mellitus (DM) in a population is one such risk factor that could lead to the development of Tuberculosis (TB) due to weakened immune functions in affected persons, with implications for mortality. If not diagnosed early, DM also leads to poor treatment outcomes in TB. Objective: To assess the prevalence of DM and impaired glucose tolerance (pre-diabetes) among newly diagnosed tuberculosis cases in Ijebu-Ode Local Government Area of Ogun State, Nigeria. Methods: This cross-sectional study was conducted among 100 newly diagnosed Pulmonary TB patients in ljebu-Ode LGA. The patients were selected from four health facilities and were screened for elevated Fasting Blood Glucose levels using a laboratory spectrophotometer (glucose oxidase method). Results: The mean age of the 100 study participants was 33 years (± 9.82), with ages within 19 -62 years. Eleven (11.0%) had elevated blood glucose levels suggestive of DM, while 20 (20.0%) had impaired fasting blood glucose levels. Among these 31 patients, 18 (58.0%) were males while 13 (42.0%) were females. The modal ages were within 20-39 years. Conclusion: Screening for DM by healthcare providers should be routinely conducted before commencing TB patients on treatment. This will aid early detection, improve treatment outcomes of TB and prevent mortality among patients with these co-morbidities.

scholarly journals Amelioration of Olanzapine-Induced Impaired Glucose Tolerance in Mice with Methanol Extract of Steamed Brassica Oleracea (Cabbage) Leaves

2020 ◽  
Vol 18 (2) ◽  
pp. 73-78
Author(s):  
Farjana Akther Noor ◽  
Songjukta Chakraborty ◽  
Christophe Wiart ◽  
Mohammed Rahmatullah
Keyword(s):  
Blood Glucose ◽  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Brassica Oleracea ◽  
Oral Glucose ◽  
Elevated Blood ◽  
High Blood Glucose ◽  
Glucose Levels ◽  
Elevated Blood Glucose ◽  
Blood Glucose Levels

Olanzapine is an antipsychotic drug and has been reported to induce impaired glucose tolerance leading to high blood glucose levels. In oral glucose tolerance tests (OGTT), methanolic extract of steamed cabbage (Brassica oleracea L. var. capitata) (MEBO) leaves have been shown to reduce elevated blood glucose levels in glucose-loaded mice. It was thus of interest to determine whether MEBO leaves can ameliorate olanzapineinduced impaired glucose tolerance in mice, which have been administered olanzapine for 28 days. Impaired glucose tolerance was measured through OGTT in mice. Olanzapine (28 days)-administered mice showed elevated blood glucose in OGTT. MEBO leaves showed significant reduction of blood glucose level in OGTT in mice (compared to vehicle or olanzapine treated mice for 28 days, Groups 2 and 3, respectively) both when administered for 28 days along with olanzapine, as well when administered 60 min prior to glucose loading in OGTT (positive control glibenclamide administered at 10 mg/kg). A single dose of MEBO (400 mg/kg) was used based on previous studies. Thus, MEBO leaves can be beneficial for improving glucose tolerance and reduce blood glucose levels in olanzapine-induced elevated blood glucose levels.

Mentha pulegium Aqueous Extract Exhibits Antidiabetic and Hepatoprotective Effects in Streptozotocin-Induced Diabetic Rats

2019 ◽  
Vol 19 (3) ◽  
pp. 292-301
Author(s):  
Omar Farid ◽  
Naoufel Ali Zeggwagh ◽  
Fadwa EL Ouadi ◽  
Mohamed Eddouks
Keyword(s):  
Blood Glucose ◽  
Glucose Tolerance ◽  
Aqueous Extract ◽  
Morphometric Analysis ◽  
Diabetic Rats ◽  
Mentha Pulegium ◽  
Glucose Levels ◽  
Histological Sections ◽  
Blood Glucose Levels ◽  
Liver And Pancreas

Objective: The aim of this work was to evaluate the antihyperglycemic activity of aerial parts aqueous extract (A.P.A.E) of Mentha pulegium (M. pulegium) on blood glucose levels in normal and streptozotocin(STZ)-induced diabetic rat. The glucose tolerance was evaluated in normal rats. Moreover, the histological sections and morphometric analysis at the liver and pancreas have been carried out in this investigation both in normal and STZ-diabetic rats. Methods: The effect of A.P.A.E of M. pulegium (20 mg/kg) on blood glucose levels was investigated in normal and diabetic rats (n=6). Histopathological changes in liver and pancreas were examined under phase contrast microscope and a preliminary screening for various bioactive constituents was realized according to standard methods. Key Findings: Both single and repeated oral administration of A.P.A.E (20 mg/kg) caused a significant reduction in blood glucose levels in STZ-diabetic rats (p<0.0001). The morphometric analysis and histological sections realized in pancreas and liver have showed the beneficial effect of the A.P.A.E in cellular population. According to oral glucose tolerance test (OGTT), the aqueous extract has revealed an improvement of glucose tolerance in normal rat. Furthermore, the preliminary phytochemical screening of A.P.A.E of M. pulegium has demonstrated the presence of various metabolite compounds including polyphenols, flavonoids, terpenoids tannins, cyanidins, sesquiterpenes, and glycosides. Conclusion: We conclude that the A.P.A.E of M. pulegium (20 mg/kg) exhibits a potent antihyperglycemic activity in STZ diabetic rats.

Sign in / Sign up

Export Citation Format

Share Document